| 34.55 -0.089 (-0.26%) | 04-24 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.88 | 1-year : | 48.92 |
| Resists | First : | 35.86 | Second : | 41.88 |
| Pivot price | 34.44  |
|||
| Supports | First : | 32.54 | Second : | 30.5 |
| MAs | MA(5) : | 34.96 |
MA(20) : | 33.89 |
| MA(100) : | 32.39 |
MA(250) : | 27.83 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 69.6 |
D(3) : | 75.3 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 37 | Low : | 20.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IBRN ] has closed below upper band by 46.6%. Bollinger Bands are 17% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.68 - 34.88 | 34.88 - 35.09 |
| Low: | 33.8 - 34.02 | 34.02 - 34.26 |
| Close: | 34.13 - 34.52 | 34.52 - 34.94 |
The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
Wed, 15 Apr 2026
(IBRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Sat, 04 Apr 2026
Liquidity Mapping Around (IBRN) Price Events - Stock Traders Daily
Mon, 09 Mar 2026
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures - Benzinga
Wed, 31 Jan 2024
Neuralink Stock Price, Symbol: How to Invest in Neuralink IPO? - CoinCodex
Wed, 15 Nov 2023
BlackRock warns of low thematic growth exposure in U.S. portfolios By Investing.com - Investing.com South Africa
Tue, 17 Jan 2023
3 Themes Growth and Tech Investors May Want to Consider in 2023 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|